News from imprimis pharmaceuticals, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Aug 12, 2015, 16:05 ET
Imprimis Pharmaceuticals Logo

Imprimis Pharmaceuticals Announces Second Quarter 2015 Financial Results and Provides Business Update

 Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary...

Aug 12, 2015, 07:30 ET
Imprimis Pharmaceuticals Logo

Imprimis Pharmaceuticals Signs License Agreement to Bring Proprietary Compounded Ophthalmic Formulations to Ophthalmologists in Canada

 Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary...

Aug 05, 2015, 07:30 ET
Imprimis Pharmaceuticals Logo

Imprimis Pharmaceuticals Expands Distribution of its Proprietary Ophthalmic and Urologic Formulations into Texas and Virginia

 Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a specialty pharmaceutical company focused on the development and commercialization of...

Aug 03, 2015, 07:30 ET
Imprimis Pharmaceuticals Logo

Imprimis Pharmaceuticals to Host its Second Quarter 2015 Financial Report, Conference Call and Webcast on August 12, 2015 at 4:30 p.m. EDT

 Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary...

Jul 01, 2015, 09:00 ET
Dropless Cataract Surgery

Imprimis Pharmaceuticals to Ring The Nasdaq Stock Market Closing Bell

 Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary...

Jun 23, 2015, 07:30 ET
Imprimis Pharmaceuticals Logo

Imprimis Pharmaceuticals Acquires Proprietary Compounded Conscious Sedation Formulations

 Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary...

May 18, 2015, 07:30 ET
Imprimis Pharmaceuticals Logo

Canadian Journal of Urology Study Highlights the Benefits of Heparin and Alkalinized Lidocaine Combination Formulation for the Relief of Interstitial Cystitis Symptoms

 Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary...

May 13, 2015, 16:05 ET
Imprimis Pharmaceuticals Logo

Imprimis Pharmaceuticals Announces First Quarter 2015 Financial Results and Provides Business Update

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary compounded...

May 12, 2015, 07:31 ET
Imprimis Pharmaceuticals Logo

Imprimis Pharmaceuticals Announces $15 Million Term Loan Agreement with Life Sciences Alternative Funding LLC

 Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary...

May 04, 2015, 07:30 ET
Imprimis Pharmaceuticals Logo

Imprimis Pharmaceuticals to Host its First Quarter 2015 Financial Report Conference Call and Webcast on May 13, 2015 at 4:30 p.m. EDT

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary compounded...

Apr 28, 2015, 07:30 ET
Imprimis Pharmaceuticals Logo

Imprimis Pharmaceuticals Now Has Exclusive US Commercial Rights to Patented Hep-Lido-A Formulation for Interstitial Cystitis

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary compounded...

Apr 15, 2015, 07:30 ET
Imprimis Pharmaceuticals Logo

Imprimis Pharmaceuticals' Ophthalmic Formulations to be Presented at the 2015 American Society of Cataract and Refractive Surgery (ASCRS) Symposium and Congress

 Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary...

Apr 02, 2015, 07:30 ET
Imprimis Pharmaceuticals Logo

Imprimis Pharmaceuticals Announces 2015 Annual Meeting of Stockholders

 Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary...

Mar 12, 2015, 16:05 ET
Imprimis Pharmaceuticals Logo

Imprimis Pharmaceuticals Announces Fourth Quarter and Year-End 2014 Financial Results and Provides Business Update

 Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary...

Mar 04, 2015, 07:30 ET
Imprimis Pharmaceuticals Logo

Imprimis Pharmaceuticals to Host its Fourth Quarter and Fiscal Year 2014 Financial Report Conference Call and Webcast on March 12, 2015 at 4:30 p.m. EDT

 Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary...

Feb 03, 2015, 07:30 ET
Imprimis Pharmaceuticals Logo

Imprimis Pharmaceuticals and Cleveland Eye Clinic Announce Positive Findings of Evaluation of LessDrops™ Combination Eye Drop Formulations Following LASIK Surgery

 Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary...

Feb 02, 2015, 16:01 ET
Imprimis Pharmaceuticals Logo

Imprimis Pharmaceuticals Announces Two Key Leadership Promotions

 Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary...

Jan 13, 2015, 07:30 ET
Imprimis Pharmaceuticals Logo

Imprimis Pharmaceuticals to Highlight its Proprietary Ophthalmic Solutions at the Hawaiian Eye 2015 and the Cataract Surgery: Telling It Like It Is! Meetings

 Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary...

Jan 08, 2015, 08:00 ET
Imprimis Pharmaceuticals Logo

Imprimis Pharmaceuticals Looks to Expand its Ophthalmology Portfolio with LessDrops™

 Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary...